FG-2216: Phase I data

In a German Phase I trial in hemodialysis patients and healthy volunteers, single doses of FG-2216 increased median EPO levels to 240.6 from 7.8 mIU/mL in 6 patients with kidneys, and to 57.8 from 4.4...